糖尿病黄斑水肿患者玻璃体内药物治疗后体液细胞因子浓度的变化

A. Fursova, A. S. Derbeneva, I. Amir, O. Kozhevnikova, D. V. Telegina, V. Devyatkin
{"title":"糖尿病黄斑水肿患者玻璃体内药物治疗后体液细胞因子浓度的变化","authors":"A. Fursova, A. S. Derbeneva, I. Amir, O. Kozhevnikova, D. V. Telegina, V. Devyatkin","doi":"10.21516/2072-0076-2023-16-2-124-129","DOIUrl":null,"url":null,"abstract":"Purpose: to analyze intraocular fluid (IOF) cytokine concentrations in patients with diabetic macular edema (DME) after intravitreal therapy with angiogenesis inhibitors or corticosteroids (CS).Materials and methods. 44 patients (45 eyes) were divided in 2 groups depending on the therapy: group 1 (n = 19) received an angiogenesis inhibitor (aflibercept) while group2 (n = 26) received CS (dexamethasone implant). They were tested for IOF cytokine levels by Milliplex® Map Human Cytokine/Chemokine Panel at treatment start and 3 months after either 3 monthly injections of aflibercept or a single dexamethasone implant injection.Results. The concentrations of ten cytokines (IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, PDGF-AA, GROα/CXCL1, VEGF-A, MIP-1β/CCL4, IL-15, IL-7, IL-6) were found to fall significantly in both groups of therapy. IL-6 and IL-5 levels showed the most significant drop as compared to other cytokines, with a more pronounced decrease in the aflibercept treatment group. In both groups, VEGF-A concentration showed a significant drop, and the share of the eyes that responded to the treatment was 94.7 % in the aflibercept therapy group and 96.2 % in in the dexamethasone implant group.Conclusion. The IOF concentration assessment of a number of pro-inflammatory cytokines/chemokines shows that both the anti-VEGF agent — aflibercept and CS — dexamethasone implant contribute to a decrease of inflammation which is observed 3 months after the start of treatment.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Aqeuous humor cytokines concentration changes in patients with diabetic macular edema after intravitreal pharmacotherapy\",\"authors\":\"A. Fursova, A. S. Derbeneva, I. Amir, O. Kozhevnikova, D. V. Telegina, V. Devyatkin\",\"doi\":\"10.21516/2072-0076-2023-16-2-124-129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: to analyze intraocular fluid (IOF) cytokine concentrations in patients with diabetic macular edema (DME) after intravitreal therapy with angiogenesis inhibitors or corticosteroids (CS).Materials and methods. 44 patients (45 eyes) were divided in 2 groups depending on the therapy: group 1 (n = 19) received an angiogenesis inhibitor (aflibercept) while group2 (n = 26) received CS (dexamethasone implant). They were tested for IOF cytokine levels by Milliplex® Map Human Cytokine/Chemokine Panel at treatment start and 3 months after either 3 monthly injections of aflibercept or a single dexamethasone implant injection.Results. The concentrations of ten cytokines (IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, PDGF-AA, GROα/CXCL1, VEGF-A, MIP-1β/CCL4, IL-15, IL-7, IL-6) were found to fall significantly in both groups of therapy. IL-6 and IL-5 levels showed the most significant drop as compared to other cytokines, with a more pronounced decrease in the aflibercept treatment group. In both groups, VEGF-A concentration showed a significant drop, and the share of the eyes that responded to the treatment was 94.7 % in the aflibercept therapy group and 96.2 % in in the dexamethasone implant group.Conclusion. The IOF concentration assessment of a number of pro-inflammatory cytokines/chemokines shows that both the anti-VEGF agent — aflibercept and CS — dexamethasone implant contribute to a decrease of inflammation which is observed 3 months after the start of treatment.\",\"PeriodicalId\":36080,\"journal\":{\"name\":\"Rossiiskii Oftal''mologicheskii Zhurnal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rossiiskii Oftal''mologicheskii Zhurnal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21516/2072-0076-2023-16-2-124-129\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rossiiskii Oftal''mologicheskii Zhurnal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21516/2072-0076-2023-16-2-124-129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:分析糖尿病黄斑水肿(DME)患者玻璃体内使用血管生成抑制剂或皮质类固醇(CS)治疗后的眼内液(IOF)细胞因子浓度。材料和方法。44例(45眼)患者根据治疗分为2组:第1组(n=19)接受血管生成抑制剂(阿飞西普),第2组(n=26)接受CS(地塞米松植入物)。Milliplex®Map人类细胞因子/趋化因子小组在治疗开始时和3个月注射阿哌西普或单次地塞米松植入物后3个月对他们进行了IOF细胞因子水平测试。后果10种细胞因子(IL-8/CXCL8、IP-10/CXCL10、MCP-1/CCL2、PDGF-AA、GROα/CXCL1、VEGF-A、MIP-1β/CCL4、IL-15、IL-7、IL-6)的浓度在两组治疗中均显著下降。与其他细胞因子相比,IL-6和IL-5水平下降最为显著,阿非利西普治疗组的下降更为明显。在这两组中,VEGF-A浓度均显著下降,对治疗有反应的眼睛比例在阿法西普治疗组为94.7%,在地塞米松植入组为96.2%。结论对一些促炎细胞因子/趋化因子的IOF浓度评估表明,抗VEGF剂——阿法西普和CS——地塞米松植入物都有助于减少炎症,这在治疗开始3个月后观察到。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Aqeuous humor cytokines concentration changes in patients with diabetic macular edema after intravitreal pharmacotherapy
Purpose: to analyze intraocular fluid (IOF) cytokine concentrations in patients with diabetic macular edema (DME) after intravitreal therapy with angiogenesis inhibitors or corticosteroids (CS).Materials and methods. 44 patients (45 eyes) were divided in 2 groups depending on the therapy: group 1 (n = 19) received an angiogenesis inhibitor (aflibercept) while group2 (n = 26) received CS (dexamethasone implant). They were tested for IOF cytokine levels by Milliplex® Map Human Cytokine/Chemokine Panel at treatment start and 3 months after either 3 monthly injections of aflibercept or a single dexamethasone implant injection.Results. The concentrations of ten cytokines (IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, PDGF-AA, GROα/CXCL1, VEGF-A, MIP-1β/CCL4, IL-15, IL-7, IL-6) were found to fall significantly in both groups of therapy. IL-6 and IL-5 levels showed the most significant drop as compared to other cytokines, with a more pronounced decrease in the aflibercept treatment group. In both groups, VEGF-A concentration showed a significant drop, and the share of the eyes that responded to the treatment was 94.7 % in the aflibercept therapy group and 96.2 % in in the dexamethasone implant group.Conclusion. The IOF concentration assessment of a number of pro-inflammatory cytokines/chemokines shows that both the anti-VEGF agent — aflibercept and CS — dexamethasone implant contribute to a decrease of inflammation which is observed 3 months after the start of treatment.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
107
审稿时长
16 weeks
期刊最新文献
Telemedicine for glaucoma: the state-of-the-art and trends of development Modifying treatment of degenerative retinal diseases. Part 2. Conditioning therapy techniques and the problem of maximizing retinal plasticity Ocular proton therapy: state-of-the-art Methodological aspects of statistical analysis in ophthalmology Keratoprostheses: from the past to the future
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1